2014年慢性病毒性肝炎临床诊疗进展*

doi:10.3969/j.issn.1672-5069.2015.01.004

Abstract

Wu Di, Ning Qin. 2014 update on the diagnosis and treatment of chronic viral hepatitis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 10-14.

[1] McBride G. Hepatitis B virus-induced liver cancer in Asian Americans:a preventable disease. J Natl Cancer Inst,2008,100（8）:528-529.
[2] Liang XF,Bi SL,Yang WZ,et a1. Reprint of: Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination.Vaccine,2013,27（31 Suppl 9）:J21-28.
[3] Liang XF,Bi SL,Yang WZ,et a1. Evaluation of the impact of hepatitis B vaccination among children born between 1992 and 2005 in China. J Infect Dis,2009,200（1）:39-47.
[4] Brunetto MR. A new role for an old marker,HBsAg. J Hepatol,2010,52（4）:475-477.
[5] Guyen T,Thompson AJ,Bowden S,et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol,2010,52（4）:508-513.
[6] Ning Q,Han M,Sun Y,et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B:A randomised open-label trial （OSST trial）. J Hepatol,2014,61（4）:777-784.
[7] Chen CH,Lu SN,Hung CH,et al. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol,2014,61（3）:515-522.
[8] Gordon SC,Krastev Z,Horban A,et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology,2013,58（2）:505-513.
[9] Rijckborst V,Hansen BE,Ferenci P,et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol,2012,56（5）:1006-10011.
[10] Rijckborst V,Hansen BE,Cakaloglu Y,et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology,2010,52（2）:454-461.
[11] Thursz M,Yee L,Khakoo S. Understanding the host genetics of chronic hepatitis B and C. Semin Liver Dis,2011,31（2）:115-127.
[12] de Groen RA1,Mcphee F,Friborg J,et al. Endogenous IFNλ in viral hepatitis patients. J Interferon Cytokine Res,2014,34（7）:552-556.
[13] Takkenberg RB,Menting S,Beld MG. Validation of a sensitive and specific real-time PCR for detection and quantitation of hepatitis B virus covalently closed circular DNA in plasma of chronic hepatitis B patients. Methods Mol Biol,2012,903:113-128.
[14] Seeger C,Mason W. Hepatitis B virus biology. Microbiol Mol Biol Rev,2000,64（1）:51-68.
[15] Hoofnagle JH,Dibisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med,1997,336（5）:347-356.
[16] Brouwer WP,Xie Q,Sonneveld MJ,et al. Adding peginterferon to entecavir for HBeAg-positive chronic hepatitis B:A multicentre randomized trial（ARES study）. Hepatology,2014[Epub ahead of print].
[17] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[18] Guo W,Wu D,Wang P,et al. A prospective,open-label cohort study comparing the efficacy,safety and drug resistance of entecavir monotherapy versus de novo combination of lamivudine and adefovir dipivoxil in naive HBeAg-positive chronic hepatitis B patients with high HBV viral load（The Climber Study）:a preliminary analysis. AASLD. 2014.
[19] Yan H,Zhong G,Xu G,et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012,13;1.
[20] Volz T,Allweiss L,Ben MBarek M,et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol, 2013,58（5）:861-867.
[21] Nkongolo S,Ni Y,Lempp FA,et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol,2014,60（4）:723-731.
[22] Carroll D. Genome engineering with zinc-finger nucleases. Genetics,2011,188（4）:773-782.
[23] Lucifora J,Xia Y,Reisinger F,et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science,2014,343（6176）,1221-1228.
[24] Lanford RE,Guerra B,Chavez D,et al. GS-9620,an oral agonist of Toll-like receptor-7,induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology,2013,144（7）:1508-1517.
[25] Dadmanesh M,Ghorban K,Hassanshahi G,et al. Current information concerning association of IL-12 and hepatitis B infection. Clin Lab, 2014,60（2）:185-191.
[26] Chen HM,Liu HL,Yang YC,et al. Serum IL-21 levels associated with chronic hepatitis B and hepatitis B-related liver failure. Exp Ther Med,2014,7（4）:1013-1019.
[27] Kapoor R,Kottilil S. Strategies to eliminate HBV infection. Future Virol,2014,9（6）:565-585.
[28] Cova L. Advances and challenges in the development of therapeutic DNA vaccines against hepatitis B virus infection. Curr Gene Ther,2014,14（3）:149-160.
[29] Fletcher SP,Delaney WE 4th. New therapeutic targets and drugs for the treatment of chronic hepatitis B. Semin Liver Dis,2013,33（2）:130-137.
[30] 中华医学会肝病学分会、中华医学会传染病与寄生虫病学分会. 丙型肝炎防治指南.中华传染病杂志,2004,22（2）:131-136 .
[31] Park SH,Park CK,Lee JW,et al. Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea:a multi-center,retrospective observational study. Gut Liver,2012,6（1）:98-106.
[32] Shimada N1,Toyoda H,Tsubota A,et al. Baseline factors and very early viral response （week 1） for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study. J Gastroenterol,2014,49（11）:1485-1494.
[33] Lin CL,Kao JH. The clinical implications of hepatitis B virus genotype:recent advances. J Gastroenterol Hepatol,2011,26（Suppl 1）:123-130.
[34] Cobsen IM,Brown RS Jr,Freilich B,et a1.Pegintefferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients:a randomized trial. Hepatology,2007,46（4）:971-981.
[35] 慢性丙型肝炎抗病毒治疗专家委员会. 慢性丙型肝炎抗病毒治疗专家共识. 中华实验和临床感染病杂志,2009,3（3）:59-64.
[36] Grebely J,Petoumenos K,Hellard M,et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology,2010,52（4）:1216-1224.
[37] McCarthy JJ,Li JH,Thompson A,et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology,2010,138（7）:2307-2314.
[38] Sarrazin C,Susser S,Doehring A,et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol,2011,54（3）:1099-1106.
[39] Rauch A,Kutalik Z,Descombes P,et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure:a genome-wide association study. Gastroenterology, 2010,138（4）:1338-1345.
[40] European Association of the Study of the Liver. 2011 European association of the study of the liver hepatitis C virus clinical practice guidelines. Liver Int,2012,32（1）:2-8.
[41] Hayes NC,Chayama K. Emerging treatments for chronic hepatitis C. J Formos Med Assoc,2014,1-12[Epub ahead of print].
[42] Marc GG,David RN,Doris BS,et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American association for the study of liver diseases. J Hepatol,2011,54（4）:1433-1444.

2014 update on the diagnosis and treatment of chronic viral hepatitis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[3]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[4]	Han Meiling, Chen Ping. Antiviral therapy in patients with liver cirrhosis and thrombocytopenia [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 466-469.
[5]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.
[6]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[7]	Zhang Qian, Hu Peng. Highlights in antiviral therapy for chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 313-317.
[8]	Wang Baodan, Li Meng, Gao Yu. Predictive factors of response to interferon-α antiviral therapy in children with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 345-348.
[9]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[10]	Wu Jing, Dong Baoji, Wu Chao. Comparison of PD-1 receptor on peripheral blood follicular helper T lymphocyte surface in chronic hepatitis C patients with low and high serum viral loads [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 192-195.
[11]	Hou Chunyang, Ma Yumei, Li Fangzhi.. Clinical efficacy of peg-IFNα and ribavirin combination in treating patients with chronic hepatitis C and genotype one and six infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 53-56.
[12]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[13]	Wang Yaofeng.. Efficacy and safety of tenofovir in the treatment of patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 847-850.
[14]	Huang Chunming, Yang Zhan, Nie Yuqiang, et al.. Prediction of liver fibrosis by gamma-glutamyl-transpeptidase-to-platelet ratio in patients with chronic hepatitis B viral infection with normal serum transaminase levels [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 859-862.
[15]	Baoyan, Wang Yun, Xiang Xiaogang, et al.. Prognosis of patients with hepatocellular carcinoma and underlying hepatitis B An [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 924-927.